Excellence in antibody discovery and mAb characterization
Innovative platforms deliver high-affinity antibodies
IPA provides services to characterize valuable monoclonal antibodies. Specificity testing in various assays can be complemented with internalization, affinity ranking of antibody panels, and epitope binning, using BLI-based platforms. This also includes highly purified, well-characterized, low endotoxin, or labeled antibodies for various applications.
Proprietary and data-driven antibody discovery technologies and platforms feed B cell Select®, phage display, and hybridoma generation, using semi-solid media and clone picking, to deliver high affinity antibodies for your therapeutic pipeline.
Decades of experience
B cell Select
From decades of experience, the B cell Select platform allows for the interrogation of a great diversity of an animal’s antibody repertoire. Antibodies can be developed from any species (including human) or tissue, can explore the entire antibody repertoire, and identify antibodies for any possibilities in an animal’s immune repertoire including any protein class, complex therapeutic targets, post-translational modifications, and small molecules. The B cell Select technology enables the interrogation of 10 million immune cells to generate native, monoclonal antibodies from immunized animals that specifically target an antigen and allow for the rapid selection of top candidates, increasing the success rate of an antibody discovery program. The platform also harnesses the power of the immune system to generate natural pairing of the antibodies produced by selected B cells. Combining this with, for example, OmniAb® animals, offers a truly unique and superior antibody discovery option.
Select directly from B cells
Rabbits & Chickens
IPA offers rabbit and chicken monoclonal antibody development. Proprietary technology from IPA allows for the screening of the immune repertoire of the animal, creating the power to select the desired antibody directly from the B cells using our B cell Select or phage display, antibody discovery platforms.
Semi-Solid Media and Clone Picking
IPA uses proprietary, semi-solid media to grow mouse and rat hybridomas, post-fusion. This special media allows for the support and picking of single cell colonies immediately after the fusion and (hybridomas are essentially monoclonal from the start). No serial dilution (limiting dilution) cloning is required and all hybridomas that grow from the fusion can be tested for specific antibodies, within two weeks post-fusion. The quick detection of target-specific clones allows for immediate subcloning and cryopreservation of valuable cultures.
Transgenic and phage display
DeepDisplay technology utilizing a combination of any transgenic animal platform and custom IPA phage display antibody selection.
Any Ig format
Our phage display approach is based on building custom immune libraries from multiple species, including transgenic animals, or the selection of antigen-specific recombinant antibody fragments from our proprietary, pre-made human or llama phage libraries. Our libraries have been made from human patient and naïve (scFv) repertoires, as well as from naïve llama (VHH) repertoires. DeepDisplay custom immune libraries are prepared from blood, spleen, lymph nodes, and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue, and identification of unique antibodies with pre-specified characteristics.
This advanced technology allows us to express antibody fragments in bacteria or rapidly reformat into any given Ig format, such as full-size IgG of various isotypes, bispecifics, Fc mutants to modify effector functions, or chimeras with Fc regions from different species.
Varying Car-T formats
IPA supports chimeric antigen receptor (CAR) development by providing adaptable antibody discovery approaches and custom work plans designed to meet your requirements. Our diverse antibody discovery platforms, generate antibodies in different formats for CAR-T, while our precise high-throughput screening and characterization allows the inclusion of functional data early in the screening funnel. Multiple discovery methods yield broad spectrums of diverse antibodies, for further optimization with our platforms. Our human scFv library offers especially accelerates discovery timelines to complete your project with quality and efficiency.
Hybridoma cell line experts
It is critical to understand how to manage hybridoma cell lines and their potential to become unstable over time, and stop secreting antibody. With ImmunoProtect™, the DNA sequences of desirable antibodies are identified and subsequently used to produce your antibody recombinantly.
Custom assay development services fully tailored to your needs. IPA also provides assays developed in-house, available in our Products Catalog (e.g., Arthritis antibody mix (CAIA), PAD enzyme assay).
Eligible French companies involved with us in research and development may receive a tax credit. Learn More.
1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Lead the way with IPA.
We have the longest memory
Rabbit monoclonal antibodies with B Cell Select® with Function-First from IPA are unmatched for early identification of a high affinity, highly specific antibodies.
Bispecifics & IPA
Bring us your scaffold and we can do the rest. With years of experience using a variety of bi- and multi-specific modalities, IPA has end-to-end capabilities and throughput to ensure selection and development of the most relevant therapeutic candidates.
Wet lab + in silico
LENSai in silico applications for radically informed decisions are designed to lend great cost and time efficiencies, as part of the IPA antibody discovery portfolio of service.
Additional antibody discovery products